Compare FLNA & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNA | LFT |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 56.1M |
| IPO Year | N/A | N/A |
| Metric | FLNA | LFT |
|---|---|---|
| Price | $1.22 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 320.5K | 217.5K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 18.49% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $668.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $0.92 |
| 52 Week High | $2.03 | $2.45 |
| Indicator | FLNA | LFT |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 42.11 |
| Support Level | $1.16 | N/A |
| Resistance Level | $1.80 | $1.40 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 44.44 | 33.33 |
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.